SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001689813-22-000063
Filing Date
2022-08-05
Accepted
2022-08-05 16:07:16
Documents
13
Period of Report
2022-08-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K bhvn-20220805.htm   iXBRL 8-K 32700
2 EX-99.1 a2022q2bhvnearningsprex991.htm EX-99.1 211943
  Complete submission text file 0001689813-22-000063.txt   403377

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bhvn-20220805.xsd EX-101.SCH 1926
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bhvn-20220805_lab.xml EX-101.LAB 23892
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bhvn-20220805_pre.xml EX-101.PRE 12600
7 EXTRACTED XBRL INSTANCE DOCUMENT bhvn-20220805_htm.xml XML 10540
Mailing Address 215 CHURCH STREET NEW HAVEN CT 06510
Business Address 215 CHURCH STREET NEW HAVEN CT 06510 203-404-0410
Biohaven Pharmaceutical Holding Co Ltd. (Filer) CIK: 0001689813 (see all company filings)

IRS No.: 000000000 | State of Incorp.: D8 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38080 | Film No.: 221140824
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences